Cresud, a leading Argentine agricultural company, reported a net income of ARS 26,331 million for Q1 FY2027, down from ARS 146,866 million a year earlier, mainly due to losses in its urban real estate business. However, adjusted EBITDA increased by 66.4% to ARS 130,401 million, driven by strong performance in both agricultural and urban property segments. The company expects a 3.3% increase in planted area for the 2027 agricultural campaign and recently sold part of a farm in Brazil. A dividend distribution of ARS 116,000 million was also approved, reflecting confidence despite the net income decline.
CRESUD S.A.C.I.F. y A. reported its Q1 FY2027 results, showing a net income of ARS 26,331 million and a 66.4% rise in adjusted EBITDA to ARS 130,401 million. For readers following the broader market, here is Pluang's snapshot as of Nov 10, 2026 20:21 WIB: out of 150 US stocks, 52 rose and 94 fell. Notable movers include Gold Fields Limited (GFI) at USD 39.41 with a 3.97% decline and Intel Corp (INTC) at USD 57.14 down 3.76%.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
